Skip to content

Jingxiutang Pharmaceutical

Request correction

Corporate brand

Unclaimed

Jingxiutang Pharmaceutical is a traditional Chinese medicine brand.

Last updated November 4, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Jingxiutang Pharmaceutical (敬修堂药业) is identified in the supplied evidence as a traditional Chinese medicine brand. The evidence characterizes it within the broader category of Chinese medicinal products, but does not specify its founding history, ownership, headquarters, product range, or geographic markets. The subject record provides the company website, https://www.jingxiutang.com.cn. Beyond its identification as a traditional Chinese medicine brand, the available evidence does not support further claims about its present operations, corporate structure, or individual products.

History

The supplied evidence identifies Jingxiutang Pharmaceutical as a traditional Chinese medicine brand but provides no historical details. It does not establish when the brand or company was founded, who founded it, how it developed, or whether it underwent notable ownership or organizational changes. These details are therefore left unspecified.

  • Jingxiutang Pharmaceutical operates as a traditional Chinese medicine (TCM) brand specializing in 中成药 (Chinese patent medicines).

Products and positioning

Identified in the supplied evidence as a traditional Chinese medicine brand; more specific positioning is not established by the available evidence.

  • Chinese patent medicines (中成药)

    The brand's core product line consists of traditional Chinese medicine patent medicines.

Controversies

  • 2018

    Cosmetics fail standards and draw fine; drug sampling test fails

    In 2018, the 'Fibronectin Repair Dual-Effect Combo' cosmetics produced by Guangzhou Baiyunshan Jingxiutang failed hygiene standards, and it was ordered to confiscate illegal gains and fined about 45,000 yuan; in 2023, its Tianhuang Houzao Powder failed the fill-weight variation test, and the National Medical Products Administration announced it and required suspension of sales and recall. Its cross-sector cosmetics were also accused by Legal Daily of suspected medicalized false advertising such as 'preventing myopia.' Fines, recall.

Read more

Sources3 sources

Cite this profile: Cite the canonical profile. /brand-wiki/敬修堂药业 · Editorial policy · How profiles are compiled